These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 19170591)

  • 21. Intravenous polyclonal human immunoglobulins in multiple sclerosis.
    Soelberg Sorensen P
    Neurodegener Dis; 2008; 5(1):8-15. PubMed ID: 18075269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy in multiple sclerosis.
    Fernández O
    J Neurol Sci; 2007 Aug; 259(1-2):95-103. PubMed ID: 17507031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daclizumab (anti-CD25) in multiple sclerosis.
    Pfender N; Martin R
    Exp Neurol; 2014 Dec; 262 Pt A():44-51. PubMed ID: 24768797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody.
    Rose JW; Watt HE; White AT; Carlson NG
    Ann Neurol; 2004 Dec; 56(6):864-7. PubMed ID: 15499632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modern multiple sclerosis treatment - what is approved, what is on the horizon.
    Pilz G; Wipfler P; Ladurner G; Kraus J
    Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis.
    Patti F; Chisari CG; D'Amico E; Zappia M
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):341-352. PubMed ID: 29363337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.
    Sheridan JP; Robinson RR; Rose JW
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):9-19. PubMed ID: 24308792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Azathioprine and methotrexate in multiple sclerosis.
    Fernández O; Fernández V; De Ramón E
    J Neurol Sci; 2004 Aug; 223(1):29-34. PubMed ID: 15261557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practices.
    Giovannoni G; Kinkel P; Vartanian T
    Rev Neurol Dis; 2007; 4(4):184-93. PubMed ID: 18195670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of multiple sclerosis--now and in future. The Danish Multiple Sclerosis Society and the Danish Multiple Sclerosis Group].
    Sellebjerg FT; Sørensen PS;
    Ugeskr Laeger; 2007 Mar; 169(12):1121. PubMed ID: 17394832
    [No Abstract]   [Full Text] [Related]  

  • 31. What can be learned from open direct comparative trials in multiple sclerosis?
    Khan O
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S25-8. PubMed ID: 19200861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapy of multiple sclerosis].
    Simó M
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intrathecal effects of daclizumab treatment of multiple sclerosis.
    Bielekova B; Richert N; Herman ML; Ohayon J; Waldmann TA; McFarland H; Martin R; Blevins G
    Neurology; 2011 Nov; 77(21):1877-86. PubMed ID: 22076546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Combined therapy in multiple sclerosis].
    García-Merino JA; Blasco-Quítez MR; Ortiz-Benítez P; Puerta C
    Rev Neurol; 2003 Mar 16-31; 36(6):545-9. PubMed ID: 12652419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methodological problems in evaluating efficacy of a treatment in multiple sclerosis.
    Waubant E; Goodkin D
    Pathol Biol (Paris); 2000 Mar; 48(2):104-13. PubMed ID: 10815286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New options for early treatment of multiple sclerosis.
    Tintoré M
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S9-S11. PubMed ID: 19200870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating multiple sclerosis with monoclonal antibodies.
    Buttmann M; Rieckmann P
    Expert Rev Neurother; 2008 Mar; 8(3):433-55. PubMed ID: 18345973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug insight: using monoclonal antibodies to treat multiple sclerosis.
    Hohlfeld R; Wekerle H
    Nat Clin Pract Neurol; 2005 Nov; 1(1):34-44. PubMed ID: 16932490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives.
    Bar-Zohar D; Agosta F; Goldstaub D; Filippi M
    Mult Scler; 2008 Jul; 14(6):719-27. PubMed ID: 18424478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.